Insiders Bet Big on Aptevo Therapeutics as Stock Stands Low, Eyes Radiopharma Breakthroughs
Insider confidence in Aptevo’s Niowave partnership signals a high‑risk, high‑reward upside; insiders’ RSU purchases suggest long‑term conviction amid volatile, discounted stock.
3 minutes to read